Biogen · 9 hours ago
Intern, Clinical Development
Biogen is a mid-sized biotechnology company committed to delivering life-changing medicines. They are seeking a talented intern to join their Clinical Development Group, responsible for gathering and analyzing data to support clinical trial outcomes in immunology and neurology diseases.
BiotechnologyHealth CareNeuroscienceTherapeutics
Responsibilities
Gathering and analyzing data to support efforts to better understand clinical trial outcomes
Work collaboratively with team members and groups across Biogen
Identify data sources, gathering data, and conducting analyses to support disease-specific clinical trials
Explore elements of the patient journey in an effort to better understand the scientific basis for responses to therapies
Qualification
Required
Legal authorization to work in the U.S
At least 18 years of age prior to the scheduled start date
Be currently enrolled in an accredited college or university
Degree-seeking college coursework in a scientific field required
Experience in biological understanding of human disease, especially neuroscience or immunology
Interest in clinical trials
Familiarity with analysis and interpretation of experimental results
Ability to work collaboratively with team members and groups across Biogen
Preferred
Grade point average of 3.2 or higher preferred
Benefits
Company paid holidays
Commuter benefits
Employee Resource Groups participation
80 hours of sick time per calendar year
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
H1B Sponsorship
Biogen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (100)
2024 (93)
2023 (101)
2022 (134)
2021 (104)
2020 (114)
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-08-28Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Recent News
2026-01-16
2026-01-16
Company data provided by crunchbase